|
1
|
Bai X, Ma Y and Zhang G: Butein suppresses
cervical cancer growth through the PI3K/AKT/mTOR pathway. Oncol
Rep. 33:3085–3092. 2015.PubMed/NCBI
|
|
2
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arikan SK, Kasap B, Yetimalar H, Yildiz A,
Sakarya DK and Tatar S: Impact of prognostic factors on survival
rates in patients with ovarian carcinoma. Asian Pac J Cancer Prev.
15:6087–6094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muccioli M and Benencia F: Toll-like
receptors in ovarian cancer as targets for immunotherapies. Front
Immunol. 5:3412014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Teo MC: Update on the management and the
role of intraperitoneal chemotherapy for ovarian cancer. Curr Opin
Obstet Gynecol. 26:3–8. 2013. View Article : Google Scholar
|
|
7
|
Wei W, Dizon D, Vathipadiekal V and Birrer
MJ: Ovarian cancer: Genomic analysis. Ann Oncol. 24 Suppl
10:x7–x15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y, Gou WF, Chen S, Takano Y, Xiu YL
and Zheng HC: BTG1 expression correlates with the pathogenesis and
progression of ovarian carcinomas. Int J Mol Sci. 14:19670–19680.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bookman MA: First-line chemotherapy in
epithelial ovarian cancer. Clin Obstet Gynecol. 55:96–113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raja FA, Counsell N, Colombo N, Pfisterer
J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS,
Plante M, et al: Platinum versus platinum-combination chemotherapy
in platinum-sensitive recurrent ovarian cancer: A meta-analysis
using individual patient data. Ann Oncol. 24:3028–3034. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schwab CL, English DP, Roque DM and Santin
AD: Taxanes: Their impact on gynecologic malignancy. Anticancer
Drugs. 25:522–535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pellicciotta I, Yang CP, Venditti CA,
Goldberg GL and Shahabi S: Response to microtubule-interacting
agents in primary epithelial ovarian cancer cells. Cancer Cell Int.
13:332013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sorbe B, Graflund M, Nygren L and Horvath
G: A study of docetaxel weekly or every three weeks in combination
with carboplatin as first line chemotherapy in epithelial ovarian
cancer: Hematological and non-hematological toxicity profiles.
Oncol Lett. 5:1140–1148. 2013.PubMed/NCBI
|
|
14
|
Colombo PE, Fabbro M, Theillet C, Bibeau
F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to
treatment in the primary management of epithelial ovarian cancer.
Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leamon CP, Lovejoy CD and Nguyen B:
Patient selection and targeted treatment in the management of
platinum-resistant ovarian cancer. Pharmgenomics Pers Med.
6:113–125. 2013.PubMed/NCBI
|
|
16
|
Lopez J, Banerjee S and Kaye SB: New
developments in the treatment of ovarian cancer-future
perspectives. Ann Oncol. 24 Suppl 10:x69–x76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cort A and Ozben T: Natural product
modulators to overcome multidrug resistance in cancer. Nutr Cancer.
67:411–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Si M, Zhao J, Li X, Tian JG, Li YG and Li
JM: Reversion effects of curcumin on multidrug resistance of
MNNG/HOS human osteosarcoma cells in vitro and in vivo through
regulation of P-glycoprotein. Chin Med J (Engl). 126:4116–4123.
2013.PubMed/NCBI
|
|
19
|
Abdallah HM, Al-Abd AM, El-Dine RS and
El-Halawany AM: P-glycoprotein inhibitors of natural origin as
potential tumor chemo-sensitizers: A review. J Adv Res. 6:45–62.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bansal T, Jaggi M, Khar RK and Talegaonkar
S: Emerging significance of flavonoids as P-glycoprotein inhibitors
in cancer chemotherapy. J Pharm Pharm Sci. 12:46–78. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee CH: Reversing agents for ATP-binding
cassette drug transporters. Methods Mol Biol. 596:325–340. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: Evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL,
Ren F and Li GF: Grape seed procyanidin reversal of p-glycoprotein
associated multi-drug resistance via down-regulation of NF-κB and
MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One.
8:e710712013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abouzeid AH, Patel NR, Sarisozen C and
Torchilin VP: Transferrin-targeted polymeric micelles co-loaded
with curcumin and paclitaxel: Efficient killing of
paclitaxel-resistant cancer cells. Pharm Res. 31:1938–1945. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sarisozen C, Abouzeid AH and Torchilin VP:
The effect of co-delivery of paclitaxel and curcumin by
transferrin-targeted PEG-PE-based mixed micelles on resistant
ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm
Biopharm. 88:539–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS,
Shih IeM and Choi JH: Tectorigenin sensitizes paclitaxel-resistant
human ovarian cancer cells through downregulation of the Akt and
NFκB pathway. Carcinogenesis. 33:2488–2498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Liu P, Mao H, Wanga A and Zhang X:
Emodin sensitizes paclitaxel-resistant human ovarian cancer cells
to paclitaxel-induced apoptosis in vitro. Oncol Rep. 21:1605–1610.
2009.PubMed/NCBI
|
|
28
|
Zhou L, Liu P, Chen B, Wang Y, Wang X,
Internati M Chiriva, Wachtel MS and Frezza EE: Silibinin restores
paclitaxel sensitivity to paclitaxel-resistant human ovarian
carcinoma cells. Anticancer Res. 28:1119–1127. 2008.PubMed/NCBI
|
|
29
|
Iwanski GB, Lee DH, En-Gal S, Doan NB,
Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH and
Koeffler HP: Cucurbitacin B, a novel in vivo potentiator of
gemcitabine with low toxicity in the treatment of pancreatic
cancer. Br J Pharmacol. 160:998–1007. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aribi A, Gery S, Lee DH, Thoennissen NH,
Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, et al:
The triterpenoid cucurbitacin B augments the antiproliferative
activity of chemotherapy in human breast cancer. Int J Cancer.
132:2730–2737. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dakeng S, Duangmano S, Jiratchariyakul W,
U-Pratya Y, Bögler O and Patmasiriwat P: Inhibition of Wnt
signaling by cucurbitacin B in breast cancer cells: Reduction of
Wnt-associated proteins and reduced translocation of
galectin-3-mediated β-catenin to the nucleus. J Cell Biochem.
113:49–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao Y, Islam MS, Tian J, Lui VW and Xiao
D: Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive
compound from cucumber, inhibits prostate cancer growth. Cancer
Lett. 349:15–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo J, Wu G, Bao J, Hao W, Lu J and Chen
X: Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell
cycle arrest in a ROS-dependent manner. PLoS One. 9:e881402014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo J, Zhao W, Hao W, Ren G, Lu J and Chen
X: Cucurbitacin B induces DNA damage, G2/M phase arrest, and
apoptosis mediated by reactive oxygen species (ROS) in leukemia
K562 cells. Anticancer Agents Med Chem. 14:1146–1153. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gupta P and Srivastava SK: Inhibition of
integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in
vivo breast tumor growth suppression. Oncotarget. 5:1812–1828.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma J, Zi Jiang Y, Shi H, Mi C, Li J, Nan J
Xing, Wu X, Lee J Joon and Jin X: Cucurbitacin B inhibits the
translational expression of hypoxia-inducible factor-1α. Eur J
Pharmacol. 723:46–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shang Y, Guo XX, Li WW, Rao W, Chen ML, Mu
LN and Li SJ: Cucurbitacin-B inhibits neuroblastoma cell
proliferation through up-regulation of PTEN. Eur Rev Med Pharmacol
Sci. 18:3297–3303. 2014.PubMed/NCBI
|
|
38
|
Yin D, Wakimoto N, Xing H, Lu D, Huynh T,
Wang X, Black KL and Koeffler HP: Cucurbitacin B markedly inhibits
growth and rapidly affects the cytoskeleton in glioblastoma
multiforme. Int J Cancer. 123:1364–1375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang M, Zhang H, Sun C, Shan X, Yang X,
Li-Ling J and Deng Y: Targeted constitutive activation of signal
transducer and activator of transcription 3 in human hepatocellular
carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol.
63:635–642. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang M, Sun C, Shan X, Yang X, Li-Ling J
and Deng Y: Inhibition of pancreatic cancer cell growth by
cucurbitacin B through modulation of signal transducer and
activator of transcription 3 signaling. Pancreas. 39:923–929. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang M, Bian ZG, Zhang Y, Wang JH, Kan L,
Wang X, Niu HY and He P: Cucurbitacin B inhibits proliferation and
induces apoptosis via STAT3 pathway inhibition in A549 lung cancer
cells. Mol Med Rep. 10:2905–2911. 2014.PubMed/NCBI
|
|
42
|
Zheng Q, Liu Y, Liu W, Ma F, Zhou Y, Chen
M, Chang J, Wang Y, Yang G and He G: Cucurbitacin B inhibits growth
and induces apoptosis through the JAK2/STAT3 and MAPK pathways in
SH-SY5Y human neuroblastoma cells. Mol Med Rep. 10:89–94.
2014.PubMed/NCBI
|
|
43
|
Shi W, Li X, Hou X, Peng H, Jiang Q, Shi
M, Ji Y, Liu X and Liu J: Differential apoptosis gene expressions
of rhabdomyosarcoma cells in response to enterovirus 71 infection.
BMC Infect Dis. 12:3272012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Correia C, Lee SH, Meng XW, Vincelette ND,
Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging
understanding of Bcl-2 biology: Implications for neoplastic
progression and treatment. Biochim Biophys Acta. 1853:1658–1671.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schacter JL, Henson ES and Gibson SB:
Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1
expression in breast cancer cells. PLoS One. 9:e1003642014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li C, Sun BQ and Gai XD: Compounds from
Chinese herbal medicines as reversal agents for
P-glycoprotein-mediated multidrug resistance in tumours. Clin
Transl Oncol. 16:593–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seward SM and Winer I: Primary debulking
surgery and neoadjuvant chemotherapy in the treatment of advanced
epithelial ovarian carcinoma. Cancer Metastasis Rev. 34:5–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Januchowski R, Zawierucha P, Ruciński M
and Zabel M: Microarray-based detection and expression analysis of
extracellular matrix proteins in drug-resistant ovarian cancer cell
lines. Oncol Rep. 32:1981–1990. 2014.PubMed/NCBI
|
|
49
|
Huq F, Yu JQ, Beale P, Chan C, Arzuman L,
Nessa MU and Mazumder ME: Combinations of platinums and selected
phytochemicals as a means of overcoming resistance in ovarian
cancer. Anticancer Res. 34:541–545. 2014.PubMed/NCBI
|
|
50
|
Saxena V and Hussain MD: Polymeric mixed
micelles for delivery of curcumin to multidrug resistant ovarian
cancer. J Biomed Nanotechnol. 9:1146–1154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ren Y, Yu K, Sun S, Li Z, Yuan J, Han XD,
Shi J and Zhen L: JSI124 inhibits breast cancer cell growth by
suppressing the function of B cells via the downregulation of
signal transducer and activator of transcription 3. Oncol Lett.
8:928–932. 2014.PubMed/NCBI
|
|
52
|
Li JM, Zhang W, Su H, Wang YY, Tan CP, Ji
LN and Mao ZW: Reversal of multidrug resistance in MCF-7/Adr cells
by codelivery of doxorubicin and BCL2 siRNA using a folic
acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin
nanocarrier. Int J Nanomedicine. 10:3147–3162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jansson PJ, Yamagishi T, Arvind A,
Seebacher N, Gutierrez E, Stacy A, Maleki S, Sharp D, Sahni S and
Richardson DR: Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone
(Dp44mT) overcomes multidrug resistance by a novel mechanism
involving the hijacking of lysosomal P-glycoprotein (Pgp). J Biol
Chem. 290:9588–9603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Drinberg V, Bitcover R, Rajchenbach W and
Peer D: Modulating cancer multidrug resistance by sertraline in
combination with a nanomedicine. Cancer Lett. 354:290–298. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hu T, To KK, Wang L, Zhang L, Lu L, Shen
J, Chan RL, Li M, Yeung JH and Cho CH: Reversal of P-glycoprotein
(P-gp) mediated multidrug resistance in colon cancer cells by
cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Phytomedicine. 21:1264–1272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Januchowski R, Wojtowicz K,
Sujka-Kordowska P, Andrzejewska M and Zabel M: MDR gene expression
analysis of six drug-resistant ovarian cancer cell lines. Biomed
Res Int. 2013:2417632013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Abraham J, Salama NN and Azab AK: The role
of P-glycoprotein in drug resistance in multiple myeloma. Leuk
Lymphoma. 56:26–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tomiyasu H, Watanabe M, Sugita K,
Goto-Koshino Y, Fujino Y, Ohno K, Sugano S and Tsujimoto H:
Regulations of ABCB1 and ABCG2 expression through MAPK pathways in
acute lymphoblastic leukemia cell lines. Anticancer Res.
33:5317–5323. 2013.PubMed/NCBI
|
|
59
|
Vasconcelos FC, Silva KL, Souza PS, Silva
LF, Moellmann-Coelho A, Klumb CE and Maia RC: Variation of MDR
proteins expression and activity levels according to clinical
status and evolution of CML patients. Cytometry B Clin Cytom.
80:158–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vtorushin SV, Khristenko KY, Zavyalova MV,
Perelmuter VM, Litviakov NV, Denisov EV, Dulesova AY and
Cherdyntseva NV: The phenomenon of multi-drug resistance in the
treatment of malignant tumors. Exp Oncol. 36:144–156.
2014.PubMed/NCBI
|
|
61
|
Zhao H, Peng C, Ruan G, Zhou J, Li Y and
Hai Y: Adenovirus-delivered PDCD5 counteracts adriamycin resistance
of osteosarcoma cells through enhancing apoptosis and inhibiting
Pgp. Int J Clin Exp Med. 7:5429–5436. 2014.PubMed/NCBI
|
|
62
|
Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F,
Ding W, Wang J, Xia X, Li F, et al: Abrogation of constitutive
Stat3 activity circumvents cisplatin resistant ovarian cancer.
Cancer Lett. 341:231–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Su J, Zhou L, Xia MH, Xu Y, Xiang XY and
Sun LK: Bcl-2 family proteins are involved in the signal crosstalk
between endoplasmic reticulum stress and mitochondrial dysfunction
in tumor chemotherapy resistance. Biomed Res Int. 2014:2343702014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chakraborty S, Mazumdar M, Mukherjee S,
Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A
and Das T: Restoration of p53/miR-34a regulatory axis decreases
survival advantage and ensures Bax-dependent apoptosis of non-small
cell lung carcinoma cells. FEBS Lett. 588:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bykov VJ and Wiman KG: Mutant p53
reactivation by small molecules makes its way to the clinic. FEBS
Lett. 588:2622–2627. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Vibhuti A, Muralidhar K and Dwarakanath
BS: Differential cytotoxicity of the glycolytic inhibitor
2-deoxy-D-glucose in isogenic cell lines varying in their p53
status. J Cancer Res Ther. 9:686–692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schwermer M, Lee S, Köster J, van Maerken
T, Stephan H, Eggert A, Morik K, Schulte JH and Schramm A:
Sensitivity to cdk1-inhibition is modulated by p53 status in
preclinical models of embryonal tumors. Oncotarget. 6:15425–15435.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sabbatino F, Fusciello C, Somma D, Pacelli
R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Scarpati G Della
Vittoria, Ferrone S and Pepe S: Effect of p53 activity on the
sensitivity of human glioblastoma cells to PARP-1 inhibitor in
combination with topoisomerase I inhibitor or radiation. Cytometry
A. 85:953–961. 2014. View Article : Google Scholar : PubMed/NCBI
|
